Trial name or title |
A Phase IIa Randomized, Double‐Blind, Placebo‐controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa |
Methods |
This is a phase 2 parallel RCT |
Participants |
Participants must be aged 18 to 65 years with moderate to severe HS |
Interventions |
MEDI8968 subcutaneous injection at baseline, week 4, and week 8/saline subcutaneous injection at baseline, week 4, and week 8
|
Outcomes |
Proportion of participants achieving a clinically relevant response in the Physician Global Assessment (PGA), with score 0, 1, or 2 at 12 weeks
|
Starting date |
May 2013 |
Contact information |
Dr Robert AK Lee |
Notes |
AstraZeneca sponsors the trial |